OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for recurrent ovarian cancer in early trial
Disease control OngoingThis early-phase study tests a new drug (berzosertib) added to standard chemotherapy for women with ovarian, peritoneal, or fallopian tube cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination works better than chemo alon…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:02 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (tremelimumab) to a standard targeted therapy (olaparib) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. About 61 adults with these cancers will receive …
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
Drug cocktail shows promise for Tough-to-Treat ovarian and breast cancers
Disease control OngoingThis study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which stops cancer cells from repairing themselves)—works better than olaparib alone for people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:51 UTC
-
New drug combo shows promise in ovarian cancer trial
Disease control OngoingThis early-stage trial tests whether adding the drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for people with advanced ovarian cancer. About 25 patients with stage III or IV disease will receive the combination before surgery. The go…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for hard-to-treat ovarian cancer: three-drug showdown
Disease control OngoingThis study compares three different combinations of chemotherapy and targeted drugs in 444 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based chemotherapy. The goal is to find which combination best delays cancer growt…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug combo shows promise for returning ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, peritoneal, or fallopian tube cancer that had returned after initial treatment. The goal was to see if the drugs could slow or stop tumor growth by blocking enzymes cancer cells need …
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for Hard-to-Treat ovarian cancer: targeted drug combo under study
Disease control OngoingThis study tests whether a new drug combination (bevacizumab plus anetumab ravtansine) works better than standard chemotherapy (bevacizumab plus paclitaxel) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatme…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
Ovarian cancer drug trial tests DNA changes before surgery
Knowledge-focused OngoingThis early-phase trial is testing how the drug adavosertib affects the DNA of tumor cells in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer before they have surgery. The goal is to learn how the drug changes the cancer's DNA, which may help doctors plan bet…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 07:24 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC